Ledraxen

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous, intravenous or haemodialysis use. It prevents and treats venous thromboembolism, deep vein thrombosis, pulmonary embolism and is employed during haemodialysis to reduce clot formation.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ledraxen, a low molecular weight heparin, is employed in several thrombo‑embolic conditions to inhibit clot formation.

- Prevention of venous thromboembolism: reduces the risk of clot development in at‑risk patients. - Treatment of deep vein thrombosis: facilitates clot resolution and prevents propagation. - Treatment of pulmonary embolism: helps dissolve existing emboli and limits further clotting. - Prevention of clot formation during haemodialysis: maintains circuit patency by inhibiting coagulation.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection‑site bruising or pain. - Mild bleeding (e.g., gum or nosebleeds). - Nausea or headache. - Dizziness or transient fatigue. - Minor anemia.

Serious or Rare Side Effects: - Major hemorrhage (intracranial or gastrointestinal). - Heparin‑induced thrombocytopenia (HIT). - Spinal or epidural hematoma after neuraxial procedures. - Severe allergic reactions (anaphylaxis). - Elevated liver enzymes or hepatic dysfunction.

Careful assessment and monitoring are required when using Ledraxen.

- Assess renal function: dose adjustment may be needed in impaired kidneys. - Monitor platelet count: watch for thrombocytopenia, especially after 4–10 days. - Evaluate bleeding risk: avoid in patients with active uncontrolled bleeding. - Adjust dose in elderly or low‑body‑weight patients. - Avoid concurrent use with other anticoagulants unless medically justified. - Store at ambient temperature: keep in original pack, protect from moisture and light.

Ledraxen can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Other anticoagulants (warfarin, direct oral anticoagulants). - Systemic thrombolytics (alteplase, streptokinase). - Non‑steroidal anti‑inflammatory drugs (NSAIDs). - Antiplatelet agents (aspirin, clopidogrel). - Neuraxial anesthesia or spinal puncture procedures.

Moderate Interactions (Monitor Closely): - ACE inhibitors and diuretics (potential additive hypotensive effect). - Corticosteroids (may increase bleeding tendency). - Certain antibiotics (e.g., vancomycin) that can affect platelet function.